AstraZeneca Pharma India Ltd to launch Enhertu in January 2024

AstraZeneca Pharma India Limited will launch Enhertu in January 2024 in India.

Trastuzumab deruxtecan (Enhertu) is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen.

The company has already received the Import and Market Permission in Form CT-20 from the Drugs Controller General of India for Trastuzumab deruxtecan 100mg/5mL vial lyophilized powder for concentrate for solution for infusion (Enhertu).

Shares of AstraZeneca Pharma India Limited was last trading in BSE at Rs. 4652.40 as compared to the previous close of Rs. 4656.65. The total number of shares traded during the day was 197 in over 89 trades.

The stock hit an intraday high of Rs. 4691.75 and intraday low of 4630.00. The net turnover during the day was Rs. 917455.00.

Source : Equity Bulls

Keywords

AstraZenecaPharmaIndia INE203A01020 Trastuzumabderuxteca Enhertu January2024 IndiaLaunch